Aim: This study was conducted to evaluate the impact of genetic polymorphisms on lipid profiles of statin users. Methods: This retrospective cross-sectional study involved 229 hyperlipidaemic statin users in east coast region of Peninsular Malaysia. DNA was extracted from patients’ blood (3mL) and SNP genotyping was performed using PCR-RFLP. Lipid profiles were evaluated before and after statin administration. Multi-factorial impact on the attainment of LDL goal of <2.6mmol/L was assessed by multivariate binary regression. Results: The participants were mostly females (53.3%), Malays (96.1%) and treated with atorvastatin (64.2%). Minor allele frequency (MAF) of the studied SNPs as follow; ABCG2 rs2231142 = 0.12, ABCC2 rs717620= 0.58, APOE rs429358 and rs7412 = 0.35, GATM rs9806699 = 0.63, COQ2 rs4693075= 0.96, and APOA5 rs662799= 0.45. Before statin treatment, ABCG2 rs2231142 (P=0.035) and APOA5 rs662799 (P=0.007) carriers had greater HDL-c levels while ABCC2 rs717620 carriers had higher TC (P=0.040) and LDL-c values (P=0.022). After statin treatment, the following SNPs have affected the lipid profiles; ABCC2 rs717620 (lower TG, P=0.009), APOA5 rs662799 (higher HDL, P=0.031; lower TG, P=0.037) and ABCG2 rs2231142 (higher TC, P=0.038). Furthermore, males were affected lipid profiles significantly than females in APOA5 rs662799 (lower TG, P= 0.038; higher HDL, P= 0.006). Of all independent variables tested, only pravastatin users were predicted patient’s achieving LDL-target of <2.6 mmol/L (P=0.040, OR=0.110, 95% CI=0.013-0.902). Conclusion: ABCC2 rs717620, APOA5 rs662799 and ABCG2 rs2231142, as well patient gender, determined different lipid profiles either with or without statin treatment in a subset of Malaysian population.